Project overview
This double-blinded randomized controlled trial compared the efficacy of carbetocin and oxytocin in preventing postpartum hemorrhage (PPH) among 106 low-risk primigravida delivering vaginally. Participants were randomized to receive either 10 IU oxytocin or 100 mcg carbetocin intramuscularly after the delivery of the posterior shoulder. Primary outcomes included blood loss and hemoglobin change; secondary outcomes assessed the need for additional uterotonics, transfusions, and adverse effects. Results showed no statistically significant difference between the two groups in estimated blood loss, hemoglobin drop, or rates of PPH. Although fewer participants in the carbetocin group required extra interventions, the difference was not significant. Both drugs were well tolerated, with no major side effects reported. Given its comparable efficacy, heat stability, and single-dose regimen, carbetocin presents a practical alternative to oxytocin—particularly in low-resource settings lacking cold-chain infrastructure.
This summary describes the research topic in our project library. Research findings belong to the authors; they are not outcomes of editorial support. Authors retain responsibility for their work.
Back to this project’s library page